Alasdair is a leader in KPMG’s Precision Medicine practice. He has over 20 years' experience in strategy consulting specializing in inorganic growth, R&D and commercial strategy and portfolio optimization for biopharmaceutical, genomic, diagnostic and health system clients, as well as private investors. Alasdair has also worked with numerous pre-revenue biotechnology companies to help them shape their equity story in preparation for capital raise. As a trained cancer biologist Alasdair helps clients solve complex business problems that require deep scientific and technical knowledge, and he has worked across multiple therapeutic areas, including CNS, hematology, immunology, infectious disease, metabolic diseases, oncology, respiratory, women’s health, as well as rare and ultra-rare diseases.
